Table 3.
Variable | Pre-TASP (n = 56) | TASP (n = 72) | p Value |
---|---|---|---|
Case status | 0.04 | ||
Urgent | 6 (11) | 18 (25) | |
Emergent | 50 (89) | 54 (75) | |
| |||
Operation within 24 h of symptoms | 39 (70) | 49 (68) | 0.85 |
| |||
Operation beginning at night (5 pm–6 am) | 27 (48) | 21 (29) | 0.03 |
| |||
Redo sternotomy | 7 (13) | 8 (11) | 0.81 |
| |||
Ascending aorta replacement | 55 (98) | 72 (100) | 0.26 |
| |||
Arch replacement | 14 (25) | 70 (97) | <0.0001 |
| |||
Arch type | 0.52 | ||
Hemi-arch | 14 (25) | 68 (94) | |
Total arch | 0 | 2 (3) | |
| |||
Aortic valve resuspension | 22 (39) | 55 (76) | <0.0001 |
| |||
Aortic valve replacement | 12 (21) | 0 | <0.0001 |
| |||
Aortic valve repair | 0 | 4 (6) | 0.07 |
| |||
Aortic root replacement | 16 (29) | 17 (24) | 0.52 |
| |||
Root type | 0.001 | ||
Valve sparing (David-V) | 0 | 6 (8) | |
Mechanical composite | 15 (27) | 4 (6) | |
Stentless bioprosthetic | 0 | 4 (6) | |
Pericardial composite | 1 (2) | 3 (4) | |
| |||
Concomitant procedure | 21 (38) | 12 (17) | 0.008 |
Coronary artery bypass grafting | 16 (29) | 8 (11) | |
Mitral valve replacement | 1 (2) | 0 | |
Mitral valve repair | 1 (2) | 0 | |
Maze procedure | 1 (2) | 0 | |
Innominate bypass | 2 (4) | 0 | |
Aortic arch debranching | 0 | 1 (1) | |
Descending thoracic aortic endograft | 0 | 1 (1) | |
Atrial septal defect closure | 0 | 1 (1) | |
Pulmonary artery embolectomy | 0 | 1 (1) | |
Femoral bypass | 1 (2) | 1 (1) | |
Extracorporeal membrane oxygenation | 1 (2) | 0 | |
| |||
Aortic cross-clamp time, min | 128 ± 50 (47–301) | 122 ± 37 (48–250) | 0.62 |
| |||
Cardiopulmonary bypass time, min | 270 ± 94 (107–665) | 214 ± 48 (78–377) | <0.0001 |
| |||
Use of circulatory arrest | 38 (68) | 70 (97) | <0.0001 |
| |||
Nadir NP temperature, °C | 16.3 ± 1.4 (12.0–19.0) | 14.6 ± 1.9 (11.0–19.0) | <0.0001 |
| |||
Circulatory arrest time, min | 33 ± 12 (12–53) | 25 ± 8 (13–61) | 0.002 |
| |||
Selective cerebral perfusion | 26 (68) | 70 (100) | <0.0001 |
Antegrade cerebral perfusion | 5 (13) | 67 (96) | |
Retrograde cerebral perfusion | 21 (55) | 3 (4) | |
| |||
Recombinant activated factor VII use | 0 | 30 (42) | <0.0001 |
Values are n (%) or mean ± SD (range).
NP = nasopharyngeal; other abbreviation as in Table 1.